Exhibit 99.1 Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements – Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., August 13, 2024 – Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing or ...